Basecamp Research raises $140M to develop AI-designed drugs

By Splitfeed EditorialLast updated Sep 26, 2026, 19:17 UTC

On September 23, 2026, Basecamp Research, a London-based startup, closed a $140 million Series C funding round to advance its AI-driven drug discovery platform. The round drew backing from prominent technology investors including Nvidia and Anthropic's Anthology Fund. The company's approach centers on training AI models on genetic material gathered from biodiversity-rich environments such as rainforests, oceans, and hot springs, then using those models to design antibiotics and tools for cell therapies.

The significance of the raise extends beyond its size. Antibiotic development has long been a commercially unattractive area that large pharmaceutical companies have largely exited, making AI-driven approaches a potential route to closing a growing gap in treatment options. The involvement of Nvidia and Anthropic signals that major players in AI infrastructure and safety-focused research see biological modeling as a serious near-term application, not a distant aspiration. At the same time, CTO Phil Lorenz offered a notable caution in an interview with The Decoder, arguing that biology represents a fundamentally harder challenge for AI than language, and that strong benchmark scores on paper do not translate automatically into viable drug molecules. That gap between measurable performance and real-world utility is the central dispute in AI drug discovery right now.

None of the three camps, pro-AI, anti-AI, or middle ground, have published specific reactions to this story yet. A pro-AI camp would typically point to the scale of investor confidence, the caliber of backers like Nvidia and Anthropic, and the potential to accelerate antibiotic development as evidence that AI is delivering genuine scientific value. An anti-AI camp would likely seize on Lorenz's own warning that benchmarks do not guarantee working molecules, arguing that the gap between AI-generated outputs and clinically proven drugs remains wide and that large funding rounds can obscure that gap. A middle ground position would probably acknowledge both the genuine promise of training on underexplored biological diversity and the real difficulty of translating computational results into drugs that clear clinical trials.

The clearest near-term signal to watch is whether Basecamp Research discloses specific drug candidates or announces preclinical or clinical milestones, which would allow outside observers to test whether the platform's outputs hold up beyond benchmark performance.